samedan logo
 
 
 
spacer
home > pmps > summer 2020 > achieving zero defects in a pandemic
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Achieving Zero Defects in a Pandemic

As the COVID-19 pandemic continues to unfold, the industry is working tirelessly to identify an effective treatment and vaccine. Amid the pressure to produce a vaccine in such a short time frame, there is also the pressure to ensure no valuable time and resources are wasted. Naturally, treatments that are being considered are large molecule drugs, which require manufacturers to address challenges with achieving zero defects and silicone contamination stemming from packaging and delivery.

Drug manufacturers have always aimed to minimise time to market while also protecting injectables against contamination. However, the challenges COVID-19 has posed to global supply chains have placed even greater emphasis on this goal. According to an FDA study, developing a new medicine takes on average 10 years and costs $2.6 billion from discovery through approval. These are high stakes, so it is essential to utilise every available tool in creating an uninterrupted transition from the development stage to production.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Massimo Mainetti holds a Master's degree in Business Administration from the University of Milan, Italy. He started his career in a finance firm in London. A few years later, in 2003, he joined Panasonic Industrial Europe as Key Account Manager and then moved to a Distribution Manager role. In 2008, Massimo assumed the position of Strategic Key Account Manager at Becton & Dickinson within the Pharmaceutical Systems business unit. In January 2015, he joined the global sales team of Datwyler Pharma Packaging as Key Account Manager Injection-Systems. Since June 2017, he has been acting in his current position as Global Head of Marketing and Product Management.
spacer
Massimo Mainetti at Datwyler
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

IMFINZITM (durvalumab) WITH CHEMOTHERAPY DEMONSTRATED A SUSTAINED OVERALL SURVIVAL BENEFIT IN 1ST-LINE EXTENSIVE-STAGE SMALL CELL LUNG CANCER IN THE PHASE III CASPIAN TRIAL

Detailed results from an updated analysis of the Phase III CASPIAN trial showed AstraZenecaís Imfinzi (durvalumab) in combination with a choice of chemotherapies, etoposide plus either carboplatin or cisplatin, demonstrated a sustained, clinically meaningful overall survival (OS) benefit for adults with extensive-stage small cell lung cancer (ES-SCLC) treated in the 1st-line setting.
More info >>

White Papers

8 Ways To Reduce Tablet Manufacturing Costs

Natoli Engineering Company, Inc.

Itís no surprise that in todayís economy, companies are facing budget cuts across the board. In an effort to address these challenges, this list of 8 Ways to Reduce Tablet Manufacturing Costs was compiled.
More info >>

 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement